Spanish Registry of Renal Patients: 2022 Report and evolutive analysis

Q2 Medicine

Nefrologia English Edition Pub Date : 2025-04-01 DOI:10.1016/j.nefroe.2025.03.002

Borja Quiroga , Beatriz Mahíllo , Auxiliadora Mazuecos , Alberto Ortiz , Jordi Comas Farnés , Domingo Hernández Marrero , Sara Trujillo Alemán , M. Carmen Santiuste de Pablos , Olga Lucía Rodríguez Arévalo , María Marques Vidas , M. Fernanda Slon-Roblero , Marta Artamendi Larrañaga , Iñigo Moina Eguren , María de la Oliva Valentín Muñoz , Marta Rodríguez Camblor , Inmaculada Moreno Alia , Mª Encarnación Bouzas Caamaño , Mª Antonia Blanco Galán , Javier Deira Lorenzo , Héctor García López , Emilio Sánchez Álvarez

{"title":"Spanish Registry of Renal Patients: 2022 Report and evolutive analysis","authors":"Borja Quiroga , Beatriz Mahíllo , Auxiliadora Mazuecos , Alberto Ortiz , Jordi Comas Farnés , Domingo Hernández Marrero , Sara Trujillo Alemán , M. Carmen Santiuste de Pablos , Olga Lucía Rodríguez Arévalo , María Marques Vidas , M. Fernanda Slon-Roblero , Marta Artamendi Larrañaga , Iñigo Moina Eguren , María de la Oliva Valentín Muñoz , Marta Rodríguez Camblor , Inmaculada Moreno Alia , Mª Encarnación Bouzas Caamaño , Mª Antonia Blanco Galán , Javier Deira Lorenzo , Héctor García López , Emilio Sánchez Álvarez","doi":"10.1016/j.nefroe.2025.03.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic kidney disease (CKD) will be the second leading cause of death in Spain by 2100. The Spanish Renal Disease Registry (REER) records the incidence, prevalence and mortality of all patients requiring renal replacement therapy (RRT) in Spain.</div></div><div><h3>Methods</h3><div>Data are provided by Spanish autonomous regions and cities and the Organización Nacional de Trasplantes. Incidence and prevalence rates of RRT have been calculated (considering the Spanish population according to annual data from the Instituto Nacional de Estadística), as well as mortality of patients on RRT in our country during the period 2013–2022.</div></div><div><h3>Results</h3><div>The incidence rate of RRT increased by 21% from 2013 to 2019, and stabilized thereafter, with a value of 152.2 cases per million population (pmp) in 2022, of which 77.8% were on haemodialysis (HD), 16.7% on peritoneal dialysis (PD) and 5.5% received a preemptive kidney transplant. Diabetes was the leading cause of CKD requiring RRT (21.8%), followed by other causes (21.6%). The incidence rate of RRT was 2-fold higher in men than in women, with large regional differences (1.93-fold for men and 2.55-fold for women in regions with the highest and lowest incidence rates).</div><div>The prevalence rate of RRT was 1,391.1 pmp in 2022, showing a progressive increase over the last decade, mainly at the expense of an increase in the transplant population (765.0 pmp, 55.0%).</div><div>In 2022, 3,404 kidney transplants were performed in Spain (71.7 pmp), which situates it as a world leader. The most frequent donor type was the donor after the neurological determination of death (51.5%), followed by the donor after the circulatory determination of death (37%).</div><div>The overall annual mortality of RRT patients was 8.4% (13.8% for HD, 10.1% for PD and 3.9% for transplantation).</div></div><div><h3>Conclusions</h3><div>Although it has stabilized somewhat in recent years, the incidence and prevalence of RRT continues to rise in Spain. Additional measures must be adopted to harmonize and optimize kidney health care.</div></div>","PeriodicalId":31770,"journal":{"name":"Nefrologia English Edition","volume":"45 4","pages":"Pages 312-328"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nefrologia English Edition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2013251425000409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Chronic kidney disease (CKD) will be the second leading cause of death in Spain by 2100. The Spanish Renal Disease Registry (REER) records the incidence, prevalence and mortality of all patients requiring renal replacement therapy (RRT) in Spain.

Methods

Data are provided by Spanish autonomous regions and cities and the Organización Nacional de Trasplantes. Incidence and prevalence rates of RRT have been calculated (considering the Spanish population according to annual data from the Instituto Nacional de Estadística), as well as mortality of patients on RRT in our country during the period 2013–2022.

Results

The incidence rate of RRT increased by 21% from 2013 to 2019, and stabilized thereafter, with a value of 152.2 cases per million population (pmp) in 2022, of which 77.8% were on haemodialysis (HD), 16.7% on peritoneal dialysis (PD) and 5.5% received a preemptive kidney transplant. Diabetes was the leading cause of CKD requiring RRT (21.8%), followed by other causes (21.6%). The incidence rate of RRT was 2-fold higher in men than in women, with large regional differences (1.93-fold for men and 2.55-fold for women in regions with the highest and lowest incidence rates).

The prevalence rate of RRT was 1,391.1 pmp in 2022, showing a progressive increase over the last decade, mainly at the expense of an increase in the transplant population (765.0 pmp, 55.0%).

In 2022, 3,404 kidney transplants were performed in Spain (71.7 pmp), which situates it as a world leader. The most frequent donor type was the donor after the neurological determination of death (51.5%), followed by the donor after the circulatory determination of death (37%).

The overall annual mortality of RRT patients was 8.4% (13.8% for HD, 10.1% for PD and 3.9% for transplantation).

Conclusions

Although it has stabilized somewhat in recent years, the incidence and prevalence of RRT continues to rise in Spain. Additional measures must be adopted to harmonize and optimize kidney health care.

查看原文本刊更多论文

西班牙肾脏患者登记：2022年报告和进化分析。

导言：到 2100 年，慢性肾病（CKD）将成为西班牙的第二大死因。西班牙肾脏病登记处（REER）记录了西班牙所有需要接受肾脏替代治疗（RRT）的患者的发病率、患病率和死亡率：方法：数据由西班牙各自治区、城市和国家移植组织提供。方法：数据由西班牙各自治区、城市和全国器官移植组织提供。我们计算了2013-2022年间RRT的发病率和流行率（根据国家统计研究所的年度数据考虑西班牙人口），以及我国RRT患者的死亡率：2013年至2019年期间，RRT的发病率增加了21%，此后趋于稳定，2022年的发病率为每百万人口152.2例（pmp），其中77.8%的患者接受血液透析（HD），16.7%的患者接受腹膜透析（PD），5.5%的患者接受肾脏移植。糖尿病是导致需要进行 RRT 的慢性肾功能衰竭的主要原因（21.8%），其次是其他原因（21.6%）。男性 RRT 的发病率是女性的 2 倍，地区差异很大（在发病率最高和最低的地区，男性为 1.93 倍，女性为 2.55 倍）。2022 年，RRT 的发病率为 1,391.1 ppmp，在过去十年中呈现出逐步上升的趋势，这主要是以移植人口的增加（765.0 ppmp，55.0%）为代价的。2022 年，西班牙将进行 3,404 例肾移植手术（每年 71.7 例），居世界领先地位。最常见的供体类型是神经系统死亡后的供体（51.5%），其次是循环系统死亡后的供体（37%）。RRT患者的总体年死亡率为8.4%（HD为13.8%，PD为10.1%，移植为3.9%）：尽管近年来 RRT 的发病率和流行率有所稳定，但在西班牙仍在继续上升。必须采取更多措施来协调和优化肾脏保健。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊